Please enable JavaScript or talk to your local administrator to get JavaScript enabled.
Skip filters
Skip facets
Funder
  • 13

  • 10

  • 8

  • 7

  • 4

  • 4

  • 3

  • 2

  • 2

  • 1

Funder Group
Research Organization
FOR (ANZSRC) Category
RCDC Category
Researcher
City
State
Country
Country of Funder
Start Year
Active Year
Similar Projects for

Project

Bladder cancer chemotherapy potentiation with a multiprong arachidonic acid pathway modulator

Funder: National Cancer Institute

Funding period
USD 300 K
Funding amount
Abstract
Abstract A combination of cytotoxic chemotherapeutic drugs, such as gemcitabine and cisplatin (GC), is part of the standard of care for advanced bladder cancer. Neoadjuvant GC treatment can induce complete remission (no evidence of viable cancer cells), but less than 40% of patients respond and the regimen is toxic. Thus, there remains an unmet medical need to develop less toxic and more effective chemotherapy options for bladder cancer. We are developing an orally bioavailable drug candidate called PTUPB which has such properties. The compound has anti-inflammatory and anti-angiogenic mechanisms of action as demonstrated in several rodent models of metabolic syndrome and cancer. PTUPB potentiates cisplatin and GC efficacy in a bladder cancer mouse PDX models. We propose to extend this work to include determination of dose-dependent PK and anti-tumor activity and preliminary toxicity assessment for PTUPB as a single agent and in combination with GC therapy in an established patient derived xenograft (PDX) mouse model of bladder cancer. Progression free and overall survival will be assessed along with pharmacokinetic profiling, blood panels and histology assessment of selected tissues.

 
66
Projects
USD 24.2 M
Aggregated funding amount
USD 526 K
Average funding amount
Project list item
Intravesical delivery of an Fc-enhanced CD40 agonist antibody for the treatment of bladder cancer

Bladder Cancer Advocacy Network to Jeffrey Ravetch, David Knorr

USD 300,000
2020 - 2022
Project list item
CD40 agonism for the treatment of bladder cancer

National Cancer Institute to CHRISTOPHER STUART GARRIS

USD 64,554
2020 - 2023
Project list item
Novel recombinant BCG for immunotherapy of bladder cancer

National Cancer Institute to BORIS SHOR

USD 290,014
2018 - 2020
Project list item
Prevention of Urinary Bladder Cancer with Two Clinically-Ready Agents (Everolimus andNaproxen) When Administered in Combination

National Cancer Institute to CLINTON GRUBBS

USD 709,567
2018 - 2021
Project list item
Potentiation of Immunotherapy with targeted nanoporphyrin in bladder cancer

United States Department of Veterans Affairs to CHONG-XIAN PAN

 
2018 - 2022
Project list item
Role of B-arrestins in bladder cancer progression and response to chemotherapy

United States Department of Veterans Affairs to BAL L LOKESHWAR

 
2018 - 2022
Project list item
Regulatory networks in basal-like bladder cancer

Fondation ARC pour la Recherche sur le Cancer to Jacqueline Fontugne

 
2017 - 2019
Project list item
Studying the Effect of PPARG Pathway Modulation on Tumor Immune Microenvironment in Muscle Invasive Bladder Cancer

Congressionally Directed Medical Research Programs to Shruti D Shah

USD 262,050
2017 - 2018
Project list item
Development of Classifiers for Novel Bladder Cancer Subtypes

Congressionally Directed Medical Research Programs to Woonyoung Choi

USD 856,134
2017 - 2018
Project list item
Development of Classifiers for Novel Bladder Cancer Subtypes

Congressionally Directed Medical Research Programs to Seungchan Kim

USD 706,947
2017 - 2018
Project list item
Precision Cotargeting Tumor and Its Microenvironment in Bladder Cancer

Congressionally Directed Medical Research Programs to Hungming Lam

USD 706,000
2017 - 2018
Project list item
Organoid and single cell models of bladder cancer

National Centre for the Replacement Refinement and Reduction of Animals in Research

 
2017 - 2019
Project list item
Proteogenomic characterization of muscle invasive bladder cancer to identify mechanisms of resistance and targets for therapy

Bladder Cancer Advocacy Network to Seth P. Lerner, Susan Hilsenbeck, Matthew James Ellis, Keith Syson Chan, Jonathan Michael Levitt, Sung Yun Jung, Anna Malovannaya, Bing Zhang

USD 300,000
2017 - 2020
Project list item
Defining the translational landscape of metastatic bladder cancer and its role in therapeutic response to chemotherapy

Bladder Cancer Advocacy Network to Brian Raymond Winters

USD 1,700
2017 - 2017
Project list item
Defining the Immune Response to Chemotherapy and Chemo-Immunotherapy in Muscle-Invasive Bladder Cancer

Bladder Cancer Advocacy Network to Tracy L Rose, William Youngkwan Kim, Matthew Milowsky, Benjamin Vincent

USD 50,000
2017 - 2018
Project list item
Notch in bladder cancer: oncogene and tumour suppressor

Canadian Cancer Society to Peter Black, Colin Collins, Mads Daugaard, Yuzhuo Wang

USD 759,702
2016 - 2020
Project list item
Dissecting the Role of APOBEC3 Mutagenic Proteins as Drivers of Genomic Instability and Chemotherapy Resistance in Urothelial Carcinoma

Congressionally Directed Medical Research Programs to Bishoy M Faltas

USD 610,199
2015 - 2016
load more...